DOCSLIB.ORG

Substance Abuse Update 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SUBSTANCE ABUSE UPDATE 2007 Nurses Research Publication Nurses Research Publications, PO Box 480, Hayward, CA 94543 Copyright 8 2007, 4th edition, All Rights Reserved ALL RIGHTS RESERVED. No part of this material may be reprinted, reproduced, transmitted, stored in a retrieval system, or otherwise utilized, in any form or by any means electronic or mechanical, including photocopying or recording, now existing or hereinafter invented, nor may any part of this course be copied and used for any other purpose without the written permission from the publisher and author. For low-cost copies, contact Taylor College, Reprint Division. This course is presented by: Nurses Research Publications P.O. Box 480 Hayward, CA 94543 Phone: 510-888-9070 FAX: 510-537-3434 Email: [email protected] Notice and Disclaimers: Medicine and Nursing are ever-changing sciences. As new information is gained, changes in treatments and drug therapies are required. The author(s), editor, and publisher of this text have used every possible reliable source in order to verify information in this text, to be sure that the information is accurate and the most current and acceptable information available at the time of publication. However, due to human error and/or changes in medical science, neither the editors nor publishers nor any other parties involved in the preparation or publication of this text, warrant that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from use of such information. Readers are encouraged to confirm the information contained herein with other sources. For example, and in particular, readers should check the product information sheet for any drugs mentioned in this text that you plan to administer. This course is designed to provide nursing professionals with general information to assist in their practices and professional development. The information provided in this course is based on research and consultation with medical and nursing authorities, and is, to the best of our knowledge, current and accurate. However, this course is offered with the understanding that Taylor College is not engaged in rendering legal, nursing, or other professional advice. This course is not a substitute for seeking professional advice or conducting individual research. In applying the information provided in this course to individual circumstances, all recommendations must be considered in light of the unique circumstances of each situation. This course book is intended solely for individual use, and not for the benefit of providing advice or recommendations to third parties. Taylor College disclaims any responsibility for any adverse consequences resulting from the failure to seek medical, nursing, or other professional advice, or to conduct independent research. Taylor College further disclaims any responsibility for updating or revising any programs or publications presented, published, distributed or sponsored by Taylor College unless otherwise agreed to as part of an individual purchase contract. 2 TABLE OF CONTENTS Page Title Page.............................................................................................................1 Notices.................................................................................................................2 Table of Contents................................................................................................3 Course Outline ....................................................................................................4 Course Objectives ..............................................................................................6 CHAPTER 1 .........................................................................................................9 CHAPTER 2 The Opioids...........................................................................25 CHAPTER 3 CNS Depressants: Alcohol .................................................40 CHAPTER 4 CNS Depressants: Sedatives-Hypnotics ............................64 CHAPTER 5 Marijuana...............................................................................73 CHAPTER 6 CNS Stimulants: Amphetamines, Cocaine .........................85 CHAPTER 7 The Hallucinogens..............................................................102 CHAPTER 8 The Inhalants: Solvents, Glues, Aerosols ........................114 CHAPTER 9 Designer Drugs ...................................................................119 CHAPTER 10 Other Abused Drugs...........................................................124 CHAPTER 11 Over-the-Counter Drugs.....................................................133 CHAPTER 12 Treating Diverse Populations ............................................141 CHAPTER 13 The Impaired Health Care Professional ............................160 REFERENCES ...............................................................................................168 Pretest / Posttest .....................................................See Separate Test Booklet 3 Course Outline Chapter 1 Introduction to Chemical Dependency (substance abuse) Progression of Dependence - Chronicity and Relapse Chapter 2 The Opioids History, Current Impact, and abuse potential Chapter 3 CNS Depressants: Alcohol History, Current Impact, and abuse potential Chapter 4 CNS Depressants: Sedatives-Hypnotics History, Current Impact, and abuse potential Chapter 5 Marijuana History, Current Impact, and abuse potential Chapter 6 CNS Stimulants: Amphetamines, Cocaine History, Current Impact, and abuse potential Chapter 7 The Hallucinogens History, Current Impact, and abuse potential Chapter 8 The Inhalants: Solvents, Glues, Aerosols History, Current Impact, and abuse potential Chapter 9 Designer Drugs History, Current Impact, and abuse potential Chapter 10 Other abused Drugs History, Current Impact, and abuse potential Chapter 11 Over-the-Counter Drugs History, Current Impact, and abuse potential 4 Chapter 12 Treating Diverse Populations Basic Treatment Concepts, Treatment Issues, Counseling Skills, Support Groups, Therapeutic Approaches, Aftercare and continuing care Chapter 13 Impaired Health Care Professionals Potential for substance abuse by health care professionals, extent of the problem, Prevention and treatment concepts, Involvement by state boards of nursing 5 Course Objectives (Behavioral objectives of the course) At the end of this course, each nurse will be able to: 1. Name and discuss the concept of substance abuse as a disease condition 2. Name and discuss the symptoms of each stage of substance abuse 3. Name and discuss the attitudes and behavior characteristics of denial accompanying substance abuse 4. Name and discuss the risk factors associated with developing substance abuse 5. Discuss the historical development of treatment of substance abuse 6. Discuss the characteristics of opioid abuse and the treatment methods used for this commonly abused substance 7. Discuss the characteristics of alcohol abuse and the treatment methods used for this commonly abused substance 8. Discuss the characteristics of sedative-hypnotic abuse and the treatment methods used for this commonly abused substance 9. Discuss the characteristics of marijuana abuse and the treatment methods used for this commonly abused substance 10. Discuss the characteristics of CNS stimulant abuse and the treatment methods used for this commonly abused substance 11. Discuss the characteristics of the abuse of the hallucinogens and the treatment methods used for these commonly abused substances 12. Discuss the characteristics of the abuse of inhalants and the treatment methods used for these commonly abused substances 13. Discuss the characteristics of Adesigner drugs@ abuse and the treatment methods used for this commonly abused substance 14. Discuss the characteristics of the abuse of over-the-counter drugs and the treatment methods used for these commonly abused substances 15. Name and discuss the two major types of treatment programs presented in this text 6 16. Name and discuss 3 of the treatment modalities presented in this text 17. Name and discuss at least 3 treatment considerations in relation to health care professionals who have substance abuse problems 7 This page has been left blank intentionally. 8 CHAPTER 1 Introduction to Chemical Dependency 9 Introduction In this chapter we will use the term "substance abuse" to refer to the abuse of all the addictive drugs, dangerous drugs, or any other substances. The term will be used interchangeably with the term Adrug abuse,@ although it could be argued that these terms are slightly different in meaning. The terms Adrug dependent,@ Adependence,@ and Aaddiction@ will also be used interchangeably, although these terms do also have slightly different meanings which will be discussed in the text. In this text, we will also use the masculine terms Ahim,@ Ahis,@ Amale,@ etc. Keep in mind that in certain places in the text, Ahe@ may be used to refer to all persons of both genders. We may use the masculine term only for simplicity instead of using Ahim and her; his/hers,@ etc. In this and subsequent chapters, we will present the history of substance abuse and how it became viewed as a disease entity. We will also discuss some of the common characteristics of addiction of various substances as well as many characteristics unique to certain chemicals of abuse. This text will also present select statistics of substance abuse as
Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
  • Alcohol Effects on People; 00 Social Responsibility for the Control of the Use of Beverage; and (5) the Social Responsibility for the Treatment of Individuals

    Alcohol Effects on People; 00 Social Responsibility for the Control of the Use of Beverage; and (5) the Social Responsibility for the Treatment of Individuals

    DOC- NT RESUME ED 140 180 CG 011 461 TITLE Alcohol Education: Curriculum Guide for Grades 7-12. INSTITUTION New York State Education Dept., Albany. Bureau of Drug Education. PUB DATE 76 NOTE 144p.; For relat d document, see CG 011 462 EERS PRICE MF-$0.83 BC-$7.35 Plus Postage. DESCRIPTORS *Alcohol Education; *Alcoholic Beverages; Class Activities; Curriculum Guides; *Drinking; Drug Education; Health Education; *Learning Activities; Recreational Activities; *Secondary Education; Socially Deviant Behavior; Teaching Guides AB TRACT This curriculum guide is designed as an interdisciplinary resource on alcohol education for teachers of Grades 7-12. tevelopmental traits are discussed, and objectives and learning experiences are presented. The following topics are covered: ro the nature of alcohci;(2) factors influencing the use of alcoholic beverages; (3) alcohol effects on people; 00 social responsibility for the control of the use of beverage; and (5) the social responsibility for the treatment of individuals. A division is made between Grades 7-9 and 10-12, with each set of three grades considered separately. (Author/OLL)' Documents acquired by ERIC include many informal unpublished materials not available from other sources. ERIC makes every effort * * to obtain the best copy available. Nevertheless, items of marginal * * reproducibility are often encountered and this affects the quality * * of the microfiche and hardcopy reproductions ERIC makes available * via the ERIC Document Reproduction Service (EDRS). EDRS is not * responsible for
  • DEMAND REDUCTION a Glossary of Terms

    DEMAND REDUCTION a Glossary of Terms

    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T

    WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • The Hematological Complications of Alcoholism

    The Hematological Complications of Alcoholism

    The Hematological Complications of Alcoholism HAROLD S. BALLARD, M.D. Alcohol has numerous adverse effects on the various types of blood cells and their functions. For example, heavy alcohol consumption can cause generalized suppression of blood cell production and the production of structurally abnormal blood cell precursors that cannot mature into functional cells. Alcoholics frequently have defective red blood cells that are destroyed prematurely, possibly resulting in anemia. Alcohol also interferes with the production and function of white blood cells, especially those that defend the body against invading bacteria. Consequently, alcoholics frequently suffer from bacterial infections. Finally, alcohol adversely affects the platelets and other components of the blood-clotting system. Heavy alcohol consumption thus may increase the drinker’s risk of suffering a stroke. KEY WORDS: adverse drug effect; AODE (alcohol and other drug effects); blood function; cell growth and differentiation; erythrocytes; leukocytes; platelets; plasma proteins; bone marrow; anemia; blood coagulation; thrombocytopenia; fibrinolysis; macrophage; monocyte; stroke; bacterial disease; literature review eople who abuse alcohol1 are at both direct and indirect. The direct in the number and function of WBC’s risk for numerous alcohol-related consequences of excessive alcohol increases the drinker’s risk of serious Pmedical complications, includ- consumption include toxic effects on infection, and impaired platelet produc- ing those affecting the blood (i.e., the the bone marrow; the blood cell pre- tion and function interfere with blood cursors; and the mature red blood blood cells as well as proteins present clotting, leading to symptoms ranging in the blood plasma) and the bone cells (RBC’s), white blood cells from a simple nosebleed to bleeding in marrow, where the blood cells are (WBC’s), and platelets.
  • Criminal Law--The Chronic Alcoholic Vs. the Public Drunkenness Statute

    Criminal Law--The Chronic Alcoholic Vs. the Public Drunkenness Statute

    Volume 73 Issue 3 Issues 3 & 4 Article 6 September 1971 Criminal Law--The Chronic Alcoholic vs. the Public Drunkenness Statute James R. Gerchow West Virginia University College of Law Follow this and additional works at: https://researchrepository.wvu.edu/wvlr Part of the Criminal Law Commons Recommended Citation James R. Gerchow, Criminal Law--The Chronic Alcoholic vs. the Public Drunkenness Statute, 73 W. Va. L. Rev. (1971). Available at: https://researchrepository.wvu.edu/wvlr/vol73/iss3/6 This Student Note is brought to you for free and open access by the WVU College of Law at The Research Repository @ WVU. It has been accepted for inclusion in West Virginia Law Review by an authorized editor of The Research Repository @ WVU. For more information, please contact [email protected]. Gerchow: Criminal Law--The Chronic Alcoholic vs. the Public Drunkenness St WEST VIRGINIA LAW REVIEW [Vol. 73 and financial institutions justifies an articulated judicial pro- nouncement strictly limiting the holder-in-due-course defense in consumer sales paper transactions. This judicial declaration should provide that any one of certain minimal facts indicating a finan- cer-seller relationship constitutes a prima facie, but rebuttable showing sufficient to the financer the right to assert the defense of a holder in due course against the consumer. Traditionally it has been argued that such a strict test would limit the need- ed free movement of commercial paper. While such an argument might be reasonable in strictly commercial transactions, there is no great need for negotiable paper in the area of consumer sales. The many states that have eliminated negotiability in consumer sales by legislative act have recognized that financial institutions that have to take contractual obligations subject to buyer defenses must screen sellers, and, to a great extent, refuse financing to those who engage in fraudulent marketing techniques.
  • North Dakota Century Code T05c01

    North Dakota Century Code T05c01

    TITLE 5 ALCOHOLIC BEVERAGES CHAPTER 5-01 GENERAL PROVISIONS 5-01-01. Definitions. In this title: 1. "Alcohol" means neutral spirits distilled at or above one hundred ninety degrees proof, whether or not such product is subsequently reduced, for nonindustrial use. 2. "Alcoholic beverages" means any liquid suitable for drinking by human beings, which contains one-half of one percent or more of alcohol by volume. 3. "Beer" means any malt beverage containing one-half of one percent or more of alcohol by volume and includes an alcoholic beverage made by the fermentation of malt substitutes, including rice, grain of any kind, glucose, sugar, or molasses, which has not undergone distillation. 4. "Bottle or can" means any container, regardless of the material from which made, having a capacity less than a bulk container for use for the sale of malt beverages at retail. 5. "Direct shipper" means a person that is licensed by the commissioner and ships or causes to be shipped alcoholic beverages directly into this state to a consumer for the consumer's personal use and not for resale. 6. "Distilled spirits" means any alcoholic beverage that is not beer, wine, sparkling wine, or alcohol. 7. "In bulk" means in containers having a capacity not less than one-sixth barrel for use for the sale of malt beverages at retail. 8. "Licensed alcohol carrier" means a person licensed to transport or deliver alcoholic beverages to a consumer without first having the alcoholic beverage delivered through a wholesaler licensed in this state. 9. "Licensed logistics shipper" means a person that provides fulfillment house services, including warehousing, packaging, distribution, order processing, or shipment of alcoholic beverages on behalf of a licensed direct shipper and by way of a licensed alcohol carrier.
  • Alcohol Responsibly and Ending Tobacco Use, Plus Caffeine - Dr

    Alcohol Responsibly and Ending Tobacco Use, Plus Caffeine - Dr

    MHE-110 – Chapter Nine – Drinking Alcohol Responsibly and Ending Tobacco Use, plus Caffeine - Dr. Dave Shrock Chapter Nine Alcohol - an overview Alcohol and ending Tobacco Use 13th pp. 239-240; 12th pp. 232-223 • alcohol is the most widely used drug in the United (including caffeine) States • 86% of Americans consume alcohol 13th edition, pp. • 10% are heavy drinkers…who consume half of all the 241-269 alcohol produced 12th edition: • no other form of addiction or disability costs the US pp. 231-261 more than alcohol use/abuse annually Excessive alcohol use causes 88,000 deaths annually (chapter eight) twice as many as illicit drugs • lost work time, illness, insurance, accidents, medical costs take a toll on all of us…25% of all medical costs in the US are alcohol related Alcohol: The world’s most what is alcohol? dangerous drug? 13th, pp. 239-240; 12th pp. 232-233 The Lancet Medical Journal - 1 November, 2016 • alcohol is a byproduct of fermentation • In a recent article published in of vegetable or fruit pulp or ‘mash’ the British medical journal The this produces a concentration of Lancet, when considering the alcohol up to 14% drug’s damage to: • distillation is a further process by •one’s self capturing the vapors from heating • one’s family the mash, and mix this with water • the environment • proof is the measure of % of alcohol, which means the % • economic cost of alcohol is half of the ‘proof rating’ • Alcohol is the world’s most • some alcohol is 152 proof, or 71% alcohol most beers are damaging drug to individuals 8 proof, or 4% alcohol.
  • Vol. 81 Friday, No. 73 April 15, 2016 Pages 22173–22510

    Vol. 81 Friday, No. 73 April 15, 2016 Pages 22173–22510

    Vol. 81 Friday, No. 73 April 15, 2016 Pages 22173–22510 OFFICE OF THE FEDERAL REGISTER VerDate Sep 11 2014 19:00 Apr 14, 2016 Jkt 238001 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\15APWS.LOC 15APWS mstockstill on DSK4VPTVN1PROD with FEDWS II Federal Register / Vol. 81, No. 73 / Friday, April 15, 2016 The FEDERAL REGISTER (ISSN 0097–6326) is published daily, SUBSCRIPTIONS AND COPIES Monday through Friday, except official holidays, by the Office PUBLIC of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Subscriptions: Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Paper or fiche 202–512–1800 Committee of the Federal Register (1 CFR Ch. I). The Assistance with public subscriptions 202–512–1806 Superintendent of Documents, U.S. Government Publishing Office, Washington, DC 20402 is the exclusive distributor of the official General online information 202–512–1530; 1–888–293–6498 edition. Periodicals postage is paid at Washington, DC. Single copies/back copies: The FEDERAL REGISTER provides a uniform system for making Paper or fiche 202–512–1800 available to the public regulations and legal notices issued by Assistance with public single copies 1–866–512–1800 Federal agencies. These include Presidential proclamations and (Toll-Free) Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public interest. Assistance with Federal agency subscriptions: Documents are on file for public inspection in the Office of the Email [email protected] Federal Register the day before they are published, unless the Phone 202–741–6000 issuing agency requests earlier filing.
  • Psychostimulants Tobacco and Nicotine

    Psychostimulants Tobacco and Nicotine

    Psychostimulants Psychostimulants produce: • Increases in alertness. • Behavioral arousal. • Activation of sympathetic nervous system. • Sympathomimetic Effects Tobacco and Nicotine 1 Tobacco • Native Americans were the first to utilize tobacco. • Columbus discovered tobacco in the new world. • Tobacco use spread rapidly through Europe. Tobacco Preparations • Smoking Tobacco • Chewing Tobacco • Snuff Active ingredient is nicotine. • Named after Nicotiana. • Found only in tobacco. Behavioral / Physiological Effects of Nicotine • Pleasure/Euphoria • Sympathomimetic effects. • Increases in alertness. • Maybe overestimated? • Appetite Suppressant/Nausea • Muscle Tremor • Nesbitt’s Paradox 2 Pharmacokinetics Inhalation Absorption • Very rapid absorption. • One cigarette contains 1-5 mg nicotine. • A smoker utilizes ≈1 mg of this nicotine. • Dose control is important. • Low tar/nicotine cigarettes? Oral/Nasal Absorption • Nicotine is basic, so G.I. tract absorption is poor. • Cigarette smoke makes the saliva acidic. • Nicotine poorly absorbed in mouth. • Pipe and cigar smoke isn’t acidic. • Nicotine easily absorbed in mouth. • Nicotine from chewed tobacco and snuff absorbed through oral/nasal membranes. Nicotine easily crosses the blood brain barrier. Metabolism • 80-90% metabolized by the liver. • Remainder secreted in urine. • Half-life of ≈1 hour. 3 Pharmacodynamics - Nicotine is an agonist at nicotinic ACh receptors. • In the PNS, nicotine: • Causes adrenal medulla to release norepinephrine and epinephrine. • Sympathomimetic Effects • Activates receptors at the neuromuscular junction. • Muscle Tremor In the CNS, nicotine activates presynaptic axo-axonic receptors. A x o n 2 N T N T N T NT NT Axon 1 Dendrite NT Increases NT release from Axon 1. • Presynaptic Facilitation Many different NTs can be facilitated. • DA in the Nucleus Accumbens • Catecholamines in brainstem arousal centers.